Drug Profile
OSX 400 series
Alternative Names: OSX400Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Ossianix
- Class
- Mechanism of Action Botulinum toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Botulism
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Botulism in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Botulism in USA
- 19 Jul 2016 Preclinical trials in Botulism in USA (unspecified route)